Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ultragenyx Pharmaceutical Inc RARE

Healthcare Biotechnology
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product... see more

Recent & Breaking News (NDAQ:RARE)

Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita® (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO)

GlobeNewswire June 18, 2020

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire May 28, 2020

Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics

GlobeNewswire May 21, 2020

Ultragenyx Announces Positive Data from Confirmatory Cohort of Phase 1/2 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

GlobeNewswire May 15, 2020

Ultragenyx Announces Positive Longer-term Results from First Three Cohorts of Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency

GlobeNewswire May 13, 2020

Ultragenyx to Present at BofA Securities Global Health Care Conference

GlobeNewswire May 11, 2020

Ultragenyx Reports First Quarter 2020 Financial Results and Corporate Update

GlobeNewswire May 6, 2020

GeneTx and Ultragenyx Announce GTX-102 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman Syndrome

GlobeNewswire May 4, 2020

Ultragenyx to Host Conference Call for First Quarter 2020 Financial Results and Corporate Update

GlobeNewswire April 30, 2020

Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy 2020 Virtual Annual Meeting

GlobeNewswire April 28, 2020

Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing Technology

GlobeNewswire March 31, 2020

REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder

GlobeNewswire March 31, 2020

GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome

GlobeNewswire March 16, 2020

Ultragenyx to Present at Barclays Global Healthcare Conference

GlobeNewswire March 9, 2020

Ultragenyx Announces Planned Transition of Chief Financial Officer

GlobeNewswire March 3, 2020

Ultragenyx and Kyowa Kirin Announce FDA Acceptance and Priority Review Designation of Supplemental Biologics License Application for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)

GlobeNewswire February 27, 2020

Ultragenyx to Present at SVB Leerink Global Healthcare Conference

GlobeNewswire February 21, 2020

Ultragenyx Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update

GlobeNewswire February 13, 2020

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2019 Financial Results and Corporate Update

GlobeNewswire February 6, 2020

GeneTx and Ultragenyx Announce Investigational New Drug (IND) Application Active for GTX-102 in Patients with Angelman Syndrome

GlobeNewswire January 15, 2020